Migraine with prolonged aura: phenotype and treatment

Michele Viana, Shazia Afridi

Research output: Contribution to journalReview articlepeer-review


We review the published literature on migraine with prolonged aura (PA), specifically with regards to the phenotype and treatment options. PA is not uncommon. A recent study found that about 17% of migraine auras are prolonged and that 26% of patients with migraine with aura have experienced at least one PA. The characteristics of PA are similar to most typical auras with the exception of a higher number of aura symptoms (in particular sensory and/or dysphasic). There are no well-established treatments at present which target the aura component of migraine. Other than case reports, there have been open-label studies of lamotrigine and greater occipital nerve blocks. The only randomised, blinded, controlled trial to date has been of nasal ketamine showing some reduction in aura severity but not duration. A small open-labelled pilot study of amiloride was also promising. Larger randomised, controlled trials are needed to establish whether any of the existing or novel compounds mentioned are significantly effective and safe.

Original languageEnglish
Pages (from-to)1-7
Number of pages7
JournalNaunyn-Schmiedeberg's Archives of Pharmacology
Issue number1
Publication statusPublished - Jan 2018


  • Journal Article
  • Review


Dive into the research topics of 'Migraine with prolonged aura: phenotype and treatment'. Together they form a unique fingerprint.

Cite this